永泰生物-B(06978.HK)與華潤醫藥達成戰略合作 推進公司研發及管道產品的商業化
格隆匯9月17日丨永泰生物-B(06978.HK)宣佈,於2021年9月17日,公司與華潤醫藥集團有限公司("華潤醫藥",連同公司統稱"訂約方")訂立戰略合作框架協議,據此,訂約方同意就(i)於中國銷售及分銷EAL®;(ii)營運及研發;(iii)於深圳成立基金;及(iv)未來融資安排進行戰略合作。
根據華潤醫藥的資料,其為中國領先的醫藥集團之一,擁有強大的醫藥製造能力及龐大的醫藥銷售網絡。集團是中國一家領先的細胞免疫治療生物醫藥公司,接近15年來專注於T細胞免疫治療的研發和商業化。自2006年成立以來,公司透過應用免疫學、細胞生物學及遺傳學等先進理論,專注於研發及臨牀應用癌症及其他主要疾病的細胞免治療藥物。根據框架協議,訂約方同意加強合作及建立長期戰略合作關係符合彼等的利益。華潤醫藥及公司將利用各自的優勢,協調雙方的資源共同於中國推動細胞免疫治療行業的發展。
董事認為,訂立框架協議符合集團的商業化策略,包括於中國銷售及分銷EAL®,且董事認為,華潤醫藥為公司在細胞治療領域的重要合作伙伴,集團將可運用及藉助華潤醫藥的銷售及分銷專長及能力,推進集團的研發工作及其管道產品的商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.